ReportWire

Tag: fda

  • The Cold-Medication Racket

    The Cold-Medication Racket

    [ad_1]

    You wake up with a stuffy nose, so you head to the pharmacy, where a plethora of options awaits in the cold-and-flu aisle. Ah, how lucky you are to live in 21st-century America. There’s Sudafed PE, which promises “maximum-strength sinus pressure and nasal congestion relief.” Sounds great. Or why not grab DayQuil in case other symptoms show up, or Tylenol Cold + Flu Severe should whatever it is get really bad? Could you have allergies instead? Good thing you can get Benadryl Allergy Plus Congestion, too.

    Unfortunately for you and me and everyone else in this country, the decongestant in all of these pills and syrups is entirely ineffective. The brand names might be different, but the active ingredient aimed at congestion is the same: phenylephrine. Roughly two decades ago, oral phenylephrine began proliferating on pharmacy shelves despite mounting—and now damning—evidence that the drug simply does not work.

    “It has been an open secret among pharmacists,” says Randy Hatton, a pharmacy professor at the University of Florida, who filed a citizen petition in 2007 and again in 2015 asking the FDA to reevaluate phenylephrine. This week, an advisory panel to the FDA voted 16–0 that the drug is ineffective orally, which could pave the way for the agency to finally pull the drug.

    If so, the impact would be huge. Phenylephrine is combined with fever reducers, cough suppressants, or antihistamines in many popular multidrug products such as the aforementioned DayQuil. Americans collectively shell out $1.763 billion a year for cold and allergy meds with phenylephrine, according to the FDA, which also calls the number a likely underestimate. That’s a lot of money for a decongestant that, again, does not work.

    Over-the-counter oral decongestants weren’t always this bad. But in the early 2000s, states began restricting access to pseudoephedrine—a different drug that actually is effective against congestion—because it could be used to make meth; the Combat Methamphetamine Epidemic Act, signed in 2006, took the restrictions national. You can still buy real-deal Sudafed containing pseudoephedrine, but you have to show an ID and sign a logbook. Meanwhile, manufacturers filled over-the-counter shelves with phenylephrine replacements such as Sudafed PE. The PE is for phenylephrine, but you would be forgiven for not noticing the different name.

    “Thet switch from pseudoephedrine to phenylephrine was a big mistake,” says Ronald Eccles, who ran the Common Cold Unit at Cardiff University until his retirement. Eccles was critical of the switch back in 2006. The evidence, he wrote at the time, was already pointing to phenylephrine as a lousy oral drug.

    Problems started showing up quickly. Hatton, who was then a co-director of the University of Florida Drug Information Center, started getting a flurry of questions about phenylephrine: Does it work? What’s the right dose? Because my patients are complaining that it’s not doing anything. He decided to investigate, and he went deep. Hatton filed a Freedom of Information Act request for the data behind FDA’s initial evaluation of the drug in 1976. He soon found himself searching through a banker’s box of records, looking for studies whose raw data he and a postdoctoral resident typed up by hand to reanalyze. The 14 studies the FDA had considered at the time had mixed results. Five of the positive ones were all conducted at the same research center, whose results looked better than everyone else’s. Hutton’s team thought that was suspicious. If you excluded those studies, the drug no longer looked effective at its usual dose.

    All told, the case for phenylephrine was not great, but the case against was no slam dunk either. When Hatton and colleagues at the University of Florida, including Leslie Hendeles, filed a citizen petition, they asked the agency to increase the maximum dose to something that could be more effective. They did not ask to pull the drug entirely.

    There was more damning evidence to come, though. The petition led to a first FDA advisory committee meeting, in 2007, where scientists from a pharmaceutical company named Schering-Plough, which later became Merck, presented brand-new data. The company had begun studying the drug, Hatton and Hendeles recalled, because it was interested in replacing the pseudoepinephrine in its allergy drug Claritin-D. But these industry scientists did not come to defend phenylephrine. Instead, they dismantled the very foundation of the drug’s supposed efficacy.

    They showed that almost no phenylephrine reaches the nasal passages, where it theoretically could reduce congestion and swelling by causing blood vessels to constrict. When taken orally, most of it gets destroyed in the gut; only 1 percent is active in the bloodstream. This seemed to be borne out by what people experienced when they took the drug—which was nothing. The scientists presented two more studies that found phenylephrine to be no better than placebo in people congested because of pollen allergies.

    These studies, the FDA later wrote, were “remarkable,” changing the way the agency thought about how oral phenylephrine works in the body. But experts still weren’t ready to write the drug off entirely. The 2007 meeting ended with the advisory committee asking for data from higher doses.

    The story for phenylephrine only got worse from there. In hopes of making an effective product, Merck went to study higher doses in two randomized clinical trials published in 2015 and 2016. “We went double, triple, quadruple—showed no benefit,” Eli Meltzer, an allergist who helped conduct the trials for Merck, said at the FDA-advisory-panel meeting this week. In other words, not only is phenylephrine ineffective at the labeled dosage of 10 milligrams every four hours, it is not even effective at four times that dose. These data prompted Hatton and Hendeles to file a second citizen petition and helped prompt this week’s advisory meeting. This time, the panel didn’t need any more data. “We’re kind of beating a dead horse … This is a done deal as far as I’m concerned. It doesn’t work,” one committee member, Paul Pisarik, said at the meeting. The advisory’s 16–0 vote is not binding, though, so it’s still up to the FDA to decide what to do about phenylephrine.

    In any case, phenylephrine is not the only cold-and-flu drug with questionable effectiveness in its approved form. The common cough drugs guaifenesin and dextromethorphan have both come under fire. But we lack the robust clinical-trial data to draw a definitive conclusion on those one way or the other. “What really helped our case is the fact that Merck funded those studies,” Hatton says. And that Merck let its scientists publish them. Failed studies from drug companies usually don’t see the light of day because they present few incentives for publication. Changing the consensus on phenylephrine took an extraordinary set of circumstances.

    It also required two dogged guys who have now been at this work for nearly two decades. “We’re just a couple of older professors from the University of Florida trying to do what’s best for society,” Hatton told me. When I asked whether they would be tackling other cold medications, he demurred: “I don’t know if either one of us has another 20 years in us.” He would instead like to see public funding for trials like Merck’s to reevaluate other over-the-counter drugs.

    There are other effective decongestants on pharmacy shelves. Even though phenylephrine does not work in pill form, “phenylephrine is very effective if you spray it into the nose,” Hendeles says. Neo-Synephrine is one such phenylephrine spray. Other nasal sprays containing other decongestants, such as Afrin, are also effective. But the only other common oral decongestant is pseudoephedrine, which requires that extra step of asking the pharmacist.
    Restricting pseudoephedrine has not  curbed the meth epidemic, either. Meth-related overdoses are skyrocketing, after Mexican drug rings perfected a newer, cheap way to make methamphetamine without using pseudoephedrine at all. This actually effective drug still remains behind the counter, while ineffective ones fill the shelves.

    [ad_2]

    Sarah Zhang

    Source link

  • FDA panel says common decongestant doesn’t work

    FDA panel says common decongestant doesn’t work

    [ad_1]

    FDA panel says common decongestant doesn’t work – CBS News


    Watch CBS News



    An FDA panel said phenylephrine, a nasal decongestant found in many over-the-counter medications, doesn’t actually work.

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • Ineffective ingredient could make Dayquil, Sudafed and others disappear from store shelves

    Ineffective ingredient could make Dayquil, Sudafed and others disappear from store shelves

    [ad_1]

    Pharmacies could pull common over-the-counter cold medications, including Dayquil, Sudafed and Theraflu, from store shelves after Food and Drug Administration experts determined one of the drugs’ main ingredient doesn’t work.  

    That could leave consumers scrambling to find alternative treatments for relief from nasal congestion and drugmakers hurrying to devise new drug formulations. 

    Drugs like Sudafed, made by pharmaceutical company Johnson & Johnson, are part of a roughly $2.2 billion market for oral decongestants. Products with formulations that contain phenylephrine, the drug FDA experts deemed ineffective, make up about four-fifths of that market. 

    “Unintended consequences”?

    The Consumer Healthcare Products Association (CPHA) maintains that phenylephrine is effective and that the FDA’s guidance could have significant “negative unintended consequences.” Pulling drugs like Sudafed from store shelves would make it harder for consumers to treat mild illnesses, according to the industry trade group.

    Removing popular over-the-counter medications from the market would force some people “to find time to seek help from a pharmacist, doctor or clinic for an oral decongestant for a minor ailment they could otherwise self-treat,” the group said in a statement before the determination was made. 

    “Additionally, some consumers indicate they might delay or forgo treatment, which could lead to worsened clinical outcomes such as progression to acute sinusitis and increased demand for doctor and clinic visits over time,” CPHA said.

    Walgreens pharmacy, over-the-counter medicine, cough, cold and flu relief
    Drugs like Sudafed, from pharmaceutical company Johnson & Johnson, are part of a roughly $2.2 billion market for oral decongestants. Products with formulations that contain phenylephrine, the drug FDA experts deemed ineffective, make up about four-fifths of that market. 

    Jeff Greenberg/Education Images/Universal Images Group via Getty Images


    Which drugs contain phenylephrine?

    Phenylephrine is found in these and other OTC remedies for stuffy noses:

    • Mucinex Sinus-Max 
    • Robitussin Peak Cold Nighttime Nasal Relief
    • Sudafed PE Sinus Congestion
    • Theraflu
    • Vicks DayQuil and NyQuil Severe Cold & Flu

    Phenylephrine is also found in other types of products, such as hemorrhoid creams, but was only deemed ineffective as an ingredient in oral form.

    How big is the market for these drugs?

    All told, decongestants with phenylephrine account for roughly $1.8 billion in annual sales, according to an FDA report

    Drugmakers also market a separate class of nasal decongestants containing pseudoephedrine (PSE). In 2006, OTC medications containing PSE were moved behind the pharmacy counter because of concerns they could be used to make illicit methamphetamines, which is when formulations with phenylephrine became more popular.

    In 2022, stores sold roughly 242 million bottles or packages of OTC cold and allergy oral medications containing phenylephrine, according to the FDA. By comparison, stores that same year sold an estimated 51 million units of PSE, representing $542 million in sales in 2022. 

    “Sales of products containing PE, which amounted to only a small percentage of the market prior to 2006, have risen and displaced products containing PSE as an OTC decongestant, although sales of PSE, while smaller, remain,” the FDA concluded.

    The federal agency also acknowledged the potential “negative” impact that pulling oral PE products from shelves could have on consumers. 

    [ad_2]

    Source link

  • FDA approves new COVID boosters

    FDA approves new COVID boosters

    [ad_1]

    FDA approves new COVID boosters – CBS News


    Watch CBS News



    The FDA has approved new COVID-19 boosters designed to target the current dominant variant. The new shots could roll out as early as this week if the Centers for Disease Control and Prevention also approves them.

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • FDA approves updated Covid vaccines from Pfizer and Moderna as hospitalizations rise

    FDA approves updated Covid vaccines from Pfizer and Moderna as hospitalizations rise

    [ad_1]

    A health-care worker prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at a vaccination clinic in the Peabody Institute Library in Peabody, Massachusetts, Jan. 26, 2022.

    Vanessa Leroy | Bloomberg | Getty Images

    The Food and Drug Administration on Monday approved updated Covid vaccines from Pfizer and Moderna, putting the shots on track to reach Americans within days as U.S. hospitalizations from the virus rise.

    The new vaccines, which target the omicron variant XBB.1.5, are approved for people 12 and older and are authorized under emergency use for children 6 months through 11 years old, according to an FDA release.

    The updated vaccines from Pfizer and Moderna won’t be available to Americans just yet.

    A CDC advisory panel is scheduled to meet Tuesday to vote on a recommendation on the use of those jabs. After the CDC director signs off on those recommendations, the shots can be administered at pharmacies, health clinics and other vaccine distribution sites.

    The Biden administration said in August that it expects new single-strain vaccines from Pfizer, Moderna and Novavax targeting XBB.1.5 to be available to the public in mid-September

    The FDA did not announce a decision Monday on an updated Covid shot from Novavax, but the company said in a statement that the agency is still reviewing its vaccine. Shares of Novavax closed nearly 13% lower Monday following the approval of the other updated jabs.

    Novavax’s vaccine uses protein-based technology, a decades-old method deployed in routine vaccinations against hepatitis B and shingles. Meanwhile, Pfizer’s and Moderna’s shots use messenger RNA, which teaches cells how to make proteins that trigger an immune response against Covid.

    The upcoming arrival of updated vaccines offers some reassurance to Americans as the nation sees an increase in Covid cases and hospitalizations.

    While the shots do not target the variants dominant now, the vaccine makers have said the shots will still offer protection against those strains as children return to school and the weather gets cooler.

    “We expect this season’s vaccine to be available in the coming days, pending recommendation from public health authorities,” Pfizer CEO Albert Bourla said in a release following the approval.

    Bourla and Moderna CEO Stéphane Bancel, in a separate statement, urged Americans to receive their updated Covid shot during the same appointment as their annual flu shot.

    Hospitalizations have increased for seven straight weeks, and rose more than 15% for the week ending Aug. 26, to 17,418, according to the latest data from the CDC. But that number remains below the surge the nation saw in summer 2022, when hospitalizations climbed to more than 40,000.

    The uptick is fueled by newer — but closely related to XBB.1.5 — strains of the virus such as EG.5, or Eris. That omicron strain accounted for 21.5% of all cases as of Sept. 2, according to the CDC. 

    Meanwhile, XBB.1.5 is declining in the U.S., the CDC said. 

    A resident receives a Covid-19 booster shots at a vaccine clinic inside Trinity Evangelic Lutheran Church in Lansdale, Pennsylvania, U.S, on Tuesday, Apr. 5, 2022.

    Hannah Beier | Bloomberg | Getty Images

    Pfizer, Moderna and Novavax have released early trial data indicating their new shots provide protection against Eris.

    Both Pfizer and Moderna have also said their updated shots produced a strong immune response against BA.2.86, a highly mutated omicron subvariant that health officials are watching closely.

    “The updated vaccines are expected to provide good protection against COVID-19 from the currently circulating variants,” the FDA said in the release Monday.

    The agency noted that last year’s Covid boosters from Pfizer and Moderna are no longer authorized in the U.S.

    The upcoming vaccine rollout will be the first since the end of the U.S. Covid public health emergency, which expired in May. 

    The end of that declaration means the federal government will shift vaccine distribution to the private market, where manufacturers will sell their updated shots directly to health-care providers at higher prices. Previously, the government purchased vaccines directly from manufacturers at a discount to distribute to all Americans for free. 

    Private insurers and government payers such as Medicare, which cover the vast majority of Americans, are expected to provide the vaccines to people for no fee. Federal efforts such as the Biden administration’s Bridge Access Program aim to provide free Covid shots to uninsured people.

    The Biden administration will urge Americans to receive an updated Covid shot this fall, White House press secretary Karine Jean-Pierre said last week.

    “Vaccinations against Covid-19 remains the safest protection for avoiding hospitalization, long-term health outcomes, and death,” Jean-Pierre said during a briefing.

    But it’s unclear how many Americans will actually roll up their sleeves to get another shot in the coming months.

    Only around 17% of the U.S. population — around 56 million people — have received Pfizer’s and Moderna’s latest boosters since they were approved in September 2022, according to the CDC. 

    [ad_2]

    Source link

  • Why Are There So Many Food Recalls? | Entrepreneur

    Why Are There So Many Food Recalls? | Entrepreneur

    [ad_1]

    It’s never fun to find a foreign object in your food. And recently, there have been a series of recalls and contaminations of store-bought brands that have gone far beyond a stray hair.

    In the last few months alone, “extraneous materials” (metal fragments, rubber gaskets, insects) are among the top reasons for food recalls in the U.S., according to a report from ABC News.

    The annual Recall Index from brand protection firm Sedgwick found that, in 2022, the total number of units recalled by the FDA (which oversees 80 percent of the nation’s food supply) increased by 700% as compared to 2021. In 2022, there were 13 recalls by the U.S. Department of Agriculture’s Food Safety and Inspection Service (USDA).

    But so far in 2023, there have already been eight recalls by the USDA due to “possible foreign matter contamination.”

    Related: Trader Joe’s Is Recalling Cookies Because They May Contain Rocks

    However, the uptick in recalls doesn’t necessarily mean that the food we buy is “more contaminated” than it used to be.

    Keith Belk, director of the Center for Meat Safety and Quality at Colorado State University, told ABC that contamination detection has significantly improved in recent years, contributing to the number of recalls. Factors like new investigation tools, heightened monitoring by the FDA, and third-party testing companies have also contributed to the rising number of recalls being reported.

    Also, the FDA acknowledges that some level of contamination may be expected.

    “It is economically impractical to grow, harvest, or process raw products that are totally free of non-hazardous, naturally occurring, unavoidable defects,” the agency notes in its handbook.

    “The thing is, there’s never going to be a day where there’s zero risk associated with consuming a food product,” Belk told ABC.

    To stay on top of the risks, bookmark FoodSafety.gov and Recalls.gov.

    [ad_2]

    Madeline Garfinkle

    Source link

  • Top Benefits Of CBD: 7 Best CBD Products For Pain, Sleep, And Stress – Medical Marijuana Program Connection

    Top Benefits Of CBD: 7 Best CBD Products For Pain, Sleep, And Stress – Medical Marijuana Program Connection

    [ad_1]

    CBD is a wonder ingredient for many different types of relief — pain, sleeplessness, stress, anxiety. You name it, CBD’s got your back! Whether you’re taking it for chronic pain, insomnia, or just want something to help you relax after a long and stressful day, our selection of the best CBD products aims to deliver the top benefits of CBD oil to you at its most ideal speed and potency!

    Take a look at the amazing benefits of CBD you could be enjoying, and all our best recommendations to bring them straight to you!

    CBD for Pain Relief and Management

    One of CBD’s most famed benefits is its ability to relieve pain, inflammation, aches, soreness, and stiffness. CBD for pain relief is excellent at soothing chronic pain, arthritic pain, neuropathic pain, muscle soreness from exercise, and occasional inflammation. You won’t find any better all-natural pain relief than this!

    How to Use CBD Oil for Pain Relief

    CBD oil is a great way to start using CBD products for pain relief. CBD oil is one of the most commonly available types of CBD on the market and works wonders for your everyday needs. It’s very easy to incorporate into your daily routine and can even be mixed in with your favorite drink or food, although it’s also great by itself!

    For the best CBD oil for pain management, Wild Theory Summit CBD Oil with CBG features a powerful full spectrum blend of both CBD and CBG. Cannabigerol (CBG), while not as common as CBD, is often regarded as the “mother of all…

    Original Author Link click here to read complete story..

    [ad_2]

    MMP News Author

    Source link

  • Nestlé recalls Toll House cookie dough bars because they may contain wood fragments

    Nestlé recalls Toll House cookie dough bars because they may contain wood fragments

    [ad_1]

    Nestlé has recalled its Toll House Chocolate Chip Cookie Dough Bar because the snacks may contain wood fragments. 

    The recall, announced by the U.S. Food and Drug Administration Thursday, is limited to two batches of the Toll House Chocolate Chip Cookie Dough “break and bake” Bar produced on April 24 and 25. 

    The FDA has not received any reports of illnesses or deaths related to the product but decided to recall the product “out of an abundance of caution” following “a small number” of calls from consumers, according to the notice.  

    Nestlé has recalled its Toll House Chocolate Chip Cookie Dough Bar because the snacks may contain wood fragments. 

    verybestbaking.com (by Nesté)


    nestle-2.jpg
    The recall includes Toll House Chocolate Chip Cookie Dough with batch codes 311457531K and 311557534K with corresponding “best by” dates 8/22/23 and 10/23/23. 

    FDA


    Nestlé toll house recall batch codes

    The recall includes Toll House Chocolate Chip Cookie Dough with batch codes 311457531K and 311557534K with corresponding “best by” dates 8/22/23 and 10/23/23. Consumers who have purchased the affected cookie dough bars should not eat the potentially contaminated dough, but return the product to the store where it was purchased to get a replacement or refund, the manufacturer said. 

    The recall does not affect any other varieties of Nestlé Toll House refrigerated cookie dough in “break and bake” bars, rolls, tubs or any other Nestlé Toll House product, including Edible cookie dough. 

    Nestle did not immediately respond to CBS MoneyWatch’s request for comment. 

    Customers can contact Nestlé USA at 1-800-681-1678 for more information.

    [ad_2]

    Source link

  • Ice cream sold in 19 states is recalled due to listeria outbreak

    Ice cream sold in 19 states is recalled due to listeria outbreak

    [ad_1]

    A frozen food company from New York has recalled cups of its 8-ounce ice cream because the product might be contaminated with listeria. 

    The recall, announced by the U.S. Food and Drug Administration on Thursday, centers on Real Kosher brand Soft Serve On The Go. The FDA said it’s investigating the ice cream, which has been sold in 19 states and Washington, D.C. 

    One person in New York and another in Pennsylvania have fallen ill and needed hospitalization after eating the ice cream, FDA officials said. 

    Real Kosher has stopped producing the ice cream until the FDA finishes its investigation. The company — which also sells frozen fruit, pizza and flatbreads — said this week its other products are still safe to consume. No deaths have been reported linked to the ice cream. 

    “Our highest priority is the safety and well-being of our customers, which is why we have made the decision to recall all Soft Serve on the Go Cups,” the company said in its recall notice. “Soft Serve on the Go Cups are manufactured at their own dedicated facility. No other products are affected by this recall.”

    Recalled ice cream flavors

    According to Real Kosher, the recalled ice cream flavors are:

    • Soft Serve on the go Vanilla Chocolate
    • Soft Serve on the go Razzle
    • Soft Serve on the go Caramel
    • Soft Serve on the go Parve Vanilla Chocolate
    • Soft Serve on the go Sorbet Strawberry Mango
    • Soft Serve Lite Peanut Butter

    Soft Serve On The Go has been sold in canteens, grocery stores and convenience stores and served in schools, nursing homes and camps, according to the U.S. Centers for Disease Control and Prevention. The ice cream has also been distributed outside the U.S., to Belgium, Brazil, Canada, Mexico and the UK, the CDC said. 

    screen-shot-2023-08-11-at-10-33-49-am.png
    A New York-based frozen food company is recalling these ice cream cups because they could contain listeria. Two people have fallen ill after eating Real Kosher’s Soft Serve on the Go, according to the U.S. Food and Drug Administration. 

    U.S. Food and Drug Administration


    States impacted by the recall

    Real Kosher’s recalled ice cream was sold in the following states:

    • California
    • Colorado
    • Connecticut
    • Delaware
    • Florida
    • Illinois
    • Massachusetts
    • Maryland
    • Minnesota
    • Montana
    • North Carolina
    • New Hampshire
    • New Jersey
    • New York
    • Ohio
    • Oregon
    • Pennsylvania
    • Virginia
    • West Virginia

    The product was also sold in Washington, D.C.

    Listeria impact

    Real Kosher launched its recall after the Pennsylvania Department of Agriculture examined the ice cream product and it tested positive for listeria, the FDA said. Listeria is a bacterial infection that can cause serious and sometimes fatal illness in young children, frail or elderly people, or others with weakened immune systems. 

    Healthy people may experience symptoms like high fever, severe headache and stomach pain. The infection can also cause miscarriages and stillbirths. An estimated 1,600 Americans get listeriosis each year, and about 260 die, according to CDC data.

    Customers with the ice cream are asked to discard it or return it to where it was purchased. Retailers with Soft Serve On The Go on their shelves should count how many cups they have, throw all of them away, then tell Real Kosher how many cups were tossed so they can issue a refund. 

    Anyone with questions about the recall can contact Real Kosher at 1-845-668-4346 or info@softserveonthego.com.

    [ad_2]

    Source link

  • Birth Control Isn’t the Only Thing That Just Went Over-the-Counter

    Birth Control Isn’t the Only Thing That Just Went Over-the-Counter

    [ad_1]

    The FDA announced yesterday that it had for the first time approved a daily birth-control pill for over-the-counter sales. That’s a big change; once the product, called Opill, is on the market—which may be as soon as early 2024—Americans will be able to buy daily hormonal birth control without a prescription. That’s historic news, but hidden underneath it is another set of firsts: In the coming months, Americans will also be able to grab an over-the-counter treatment for their heavy periods, cramps, headaches, and even migraines; they’ll have prescription-free access to a drug for endometriosis and polycystic ovary syndrome; and they’ll be able to buy a medication that can mitigate the symptoms of menopause. It’s all in the same, progestin-based pill.

    The FDA’s approval only covers Opill’s use as a form of birth control, but doctors have been prescribing pills that contain progestin for noncontraceptive needs for years. For the most part, the intervention works much better when the pills include both progestin and estrogen. Adding that second hormone to the mix amplifies all of progestin’s beneficial effects, plus helps control hormonal acne. It also leaves more wiggle room in terms of timing: Progestin-only pills—sometimes called a minipill—have a much shorter half-life in the body, so if you don’t take them during the same three-hour window each day, they’re much less reliable at preventing pregnancy, says Anne-Marie Amies Oelschlager, the chief of pediatric and adolescent gynecology at Seattle Children’s. (Some women are prescribed progestin-only pills because they are particularly susceptible to certain risks associated with estrogen.)

    As a result, an over-the-counter progestin-only pill is far from the best way of treating these conditions, experts told me. “While I suppose that it could be used off-label, I would be hesitant to do that if someone was otherwise able to obtain a prescription for a combined oral contraceptive,” Erin Fleurant, a family-planning fellow at Northwestern Medicine, told me. And if progestin by itself really were the right approach, then an IUD, implant, or injection might be a more effective way to deliver the drug.

    Despite the fact that progestin on its own would not usually be a doctor’s first choice—“I generally don’t prescribe it,” Veronica Ades, the vice chair of ob/gyn at Jacobi Medical Center, told me—the drug can have meaningful benefits when taken on its own. Amies Oelschlager told me that she prescribes it to suppress patients’ periods, especially if they’re experiencing pain or heavy bleeding. Even low-dose pills (like Opill) can be helpful for controlling period- and perimenopause-related migraines, as well as mood swings from premenstrual syndrome or premenstrual dysphoric disorder.

    Progestin pills can also be used to treat endometrial hyperplasia, an abnormal thickening of the uterine lining (a.k.a. the endometrium) that can develop into cancer. Same for endometriosis, a condition that may affect up to 11 percent of American women in which endometrial tissue grows outside the uterus. Patients with PCOS produce unusually high levels of male sex hormones and, Ades said, generally have too much estrogen in their body relative to progesterone (the naturally occurring analogue of progestin). Progestin pills can help strike a healthier balance.

    Right now, patients have few options to get relief from any of those symptoms without a doctor’s help. Until Opill hits the market, the best non-prescription way to treat PCOS is with healthy eating and exercise, Amies Oelschlager told me. For heavy periods, the best option patients can buy without a prescription is an NSAID like ibuprofen. “As far as an over-the-counter, daily hormonal medication, this is the first in the United States,” she said.

    Perhaps the best circumstances for off-label use of Opill will be as a stopgap. If someone starts having abnormal bleeding or period pain but can’t get an appointment or travel to a doctor for several weeks, they could buy themselves some progestin-only pills for the interim. Opill could also be a backup plan for patients who are already taking birth-control pills for a non-birth-control purpose but can’t make it to their doctor to renew their prescription, or can’t get their prescription filled at a pharmacy.

    Still, Ades cautioned that even stopgap use might not be wise for endometriosis patients, for whom switching medications could disrupt a delicate balance of hormones and “create a cascade of problems.” Fleurant warned that some of the symptoms that progestin pills could help alleviate may also be associated with very serious conditions that need a different treatment plan. “Say someone was 45 years old and having irregular bleeding and also had a lot of other risk factors for uterine cancer. I wouldn’t want them to pick up this pill and think that that was going to cure everything,” she said. Instead, they should be seen by a health-care provider.

    For most women who need to be on birth control, a single-hormone drug like Opill is not the most reliable option; but starting next year, it could well be the most convenient. That same trade-off, between effectiveness and access, affects other uses of progestin, too.

    [ad_2]

    Rachel Gutman-Wei

    Source link

  • FDA gives full approval to a drug designed to slow Alzheimer’s disease

    FDA gives full approval to a drug designed to slow Alzheimer’s disease

    [ad_1]

    FDA gives full approval to a drug designed to slow Alzheimer’s disease – CBS News


    Watch CBS News



    The Food and Drug Administration on Thursday gave its approval to Leqembi, a drug designed to slow the progression of Alzheimer’s disease. Leqembi is not considered a cure for Alzheimer’s, but will be covered by Medicare. Dr. Jon LaPook has more.

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • WHO questions safety of aspartame. Here’s a list of popular foods, beverages with the sweetener.

    WHO questions safety of aspartame. Here’s a list of popular foods, beverages with the sweetener.

    [ad_1]

    As more Americans shy away from sugar, artificial sweeteners have stepped in to fill the gap in people’s favorite recipes, with more than 6,000 products manufactured with aspartame.

    But questions are being raised about aspartame’s safety after Reuters reported that the cancer research arm of the World Health Organization (WHO) is set to declare that the artificial sweetener is “possibly carcinogenic to humans.”

    WHO’s International Agency for Research on Cancer (IARC) has “assessed the potential carcinogenic effect of aspartame” and will release its findings on July 14, a representative at the organization told CBS MoneyWatch. They did not confirm the Reuters report about the IARC’s conclusion on aspartame’s safety. 

    The IARC examines the cancer-causing potential of substances, while another WHO group oversees recommendations about how much of a product is safe for humans to consume.

    Aspartame has been approved by the U.S. Food and Drug Administration for use in food products, with the agency concluding the additive is “safe for the general population.” But questions have lingered about aspartame’s safety, with one 2021 research paper, published in the peer-reviewed journal “Nutrients,” noting that “the results of its long-term use remain difficult to predict.”


    California considers ban on food additives linked to potential health risks

    01:42

    What is aspartame?

    Aspartame is a compound called methyl ester. The artificial sweetener, which is 200 times as potent as regular granulated sugar, entered the market as a low-calorie sweetener in 1981. Brand names include Nutrasweet, Equal and Sugar Twin. Since then, it has become a key ingredient in foods and beverages across North America, Asia and Europe, data from the National Library of Medicine shows.

    According to several studies, aspartame does not impact blood sugar or insulin levels, making it a popular sugar substitute in foods for diabetics. Manufacturers have also used aspartame in reduced-sugar and sugar-free snacks, condiments and beverages amid research that has linked excess sugar consumption to various cancers. 

    Foods that contain aspartame

    Here are some common foods and beverages that contain aspartame: 

    • Zero-sugar or diet sodas, including Diet Coke
    • Sugar-free gums, such as Trident gum
    • Reduced-sugar jams and jellies, such as Smucker’s sugar-free jams and preserves
    • Diet drink mixes, including Crystal Light
    • Reduced-sugar condiments, such as Log Cabin Sugar Free Syrup
    • Sugar-free gelatin like Sugar-free Jell-O
    • Tabletop sweeteners sold under brand names including Equal and Nutrasweet

    Neither Coca-Cola, maker of Diet Coke, nor other manufacturers of foods containing aspartame immediately returned requests for comment.

    Is aspartame dangerous?

    While several studies have determined aspartame to be safe in moderation, some research has linked aspartame consumption to cancer. One observational study of more than 100,000 adults in France concluded that individuals who consumed larger amounts of artificial sweeteners, especially aspartame, had a slightly elevated risk of cancer. 

    Aspartame may also cause headaches, seizures and depression, some studies have shown. 

    The FDA and American Cancer Society, however, both still deem aspartame safe for human consumption.  

    According to the FDA’s acceptable daily limit for artificial sweeteners, an adult weighing 150 pounds would have to ingest more than 18 cans of zero-sugar soda a day to experience severe negative health consequences from aspartame.

    [ad_2]

    Source link

  • Statement by Fragrance Creators’ President & CEO, Farah K. Ahmed, on Congress’ Support of Funding for the Modernization of Cosmetics Regulation Act

    Statement by Fragrance Creators’ President & CEO, Farah K. Ahmed, on Congress’ Support of Funding for the Modernization of Cosmetics Regulation Act

    [ad_1]

    “We are grateful to the Senate Appropriations Committee for approving the Fiscal Year 2024 appropriations bill that includes $7 million to the Food and Drug Administration (FDA) to support implementation of the Modernization of Cosmetics Regulation Act (MoCRA). 

    Fragrance plays an important role in cosmetics and personal care products; products that nurture skin health and hygiene, empower self-expression and confidence, and deliver generational delight to billions of people every day.  

    Throughout the legislative process, Fragrance Creators focused on the fragrance-related provisions of MoCRA as we worked with Congressional champions and other stakeholders to help develop and enact the law. This resulted in the FDA’s new expanded authority to develop regulations that advance sound science, safety, and innovation as well as drive consumer trust and access to a diverse and inclusive array of cosmetic and personal care products. For this, adequate funding of MoCRA implementation is critical. 

    We recognize Chair Murray and Ranking Member Collins, who helped author MoCRA, and the Subcommittee Chair and Ranking Member, Senators Heinrich and Hoeven, for their effort to include this initial implementation funding in a complex budget climate.  Coupled with an expression of support by the House Appropriations Committee last week, yesterday’s funding allocation is a step in the right direction towards fueling the FDA’s development of modernized, evidence-based cosmetics regulation that meets the needs of today’s and tomorrow’s consumer.” 

    ###

    Fragrance Creators Association is the trade association representing the majority of fragrance manufacturing in North America. We also represent fragrance-related interests along the value chain. Fragrance Creators’ member companies are diverse, including large, medium, and small-sized companies that create, manufacture, and use fragrances and scents for home care, personal care, home design, fine fragrance, and industrial and institutional products, as well as those that supply fragrance ingredients, including natural extracts and other raw materials that are used in perfumery and fragrance mixtures. Fragrance Creators established and administers the Congressional Fragrance Caucus, ensuring ongoing dialogue with members of Congress and staff. Fragrance Creators also produces The Fragrance Conservatory, the comprehensive digital resource for high-quality information about fragrance—www.fragranceconservatory.com. Learn more about Fragrance Creators at fragrancecreators.org—for people, perfume, and the planet.

    Source: Fragrance Creators Association

    [ad_2]

    Source link

  • FDA warns retailers to stop selling illegal e-cigarettes

    FDA warns retailers to stop selling illegal e-cigarettes

    [ad_1]

    FDA warns retailers to stop selling illegal e-cigarettes – CBS News


    Watch CBS News



    The Food and Drug Administration sent out nearly 200 letters to retailers nationwide Thursday warning them to stop selling certain unauthorized flavored disposable e-cigarettes which are designed to appeal to youth. Jonathan Vigliotti has details.

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • 6/22: CBS Evening News

    6/22: CBS Evening News

    [ad_1]

    6/22: CBS Evening News – CBS News


    Watch CBS News



    Missing sub imploded near Titanic’s wreckage, officials say; Frozen fruit recalled due to possible listeria contamination

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • Frozen fruit recalled due to possible listeria contamination

    Frozen fruit recalled due to possible listeria contamination

    [ad_1]

    Frozen fruit recalled due to possible listeria contamination – CBS News


    Watch CBS News



    The Food and Drug Administration announced that several brands of frozen fruit have been voluntarily recalled over the possibility they may be contaminated with listeria.

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • FDA allows temporary import of unapproved Chinese cancer drug to ease U.S. shortage

    FDA allows temporary import of unapproved Chinese cancer drug to ease U.S. shortage

    [ad_1]

    Worker labors on a production line at the factory of Qilu Pharmaceutical in Haikou, Hainan province of China, February 11, 2022.

    Su Bikun | VCG | Getty Images

    The U.S. Food and Drug Administration has authorized the temporary importation of an unapproved chemotherapy drug from China in effort to ease an acute shortage of cancer drugs in the United States, according to an update posted to the agency’s website Friday.

    Qilu Pharmaceutical, which makes and markets cisplatin injections in China, received FDA permission to export the drug to the U.S. market weeks ago, a document shows.

    A letter dated May 24 from Qilu’s deputy general manager notified health care professionals of the approval.

    Qilu is coordinating with a Toronto-based company, Apotex, to distribute 50-milligram cisplatin vials in the U.S.

    Health care providers can begin ordering the drug Tuesday through their wholesalers.

    Cisplatin is a generic drug that has been available for decades in the U.S. and is distributed by several approved manufacturers. Those manufacturers have been unable to keep up with demand. Qilu’s version of cisplatin is not approved in the U.S.

    Qilu, which is headquartered in the city of Jinan in Shandong province, says it is one of the 10 largest drug manufacturers in China.

    The FDA told CNBC this week the agency was considering imports of unapproved chemotherapy drugs, but it did not at that time disclose the names of any manufacturers who might provide that medication.

    An FDA spokesperson said the agency assesses the quality of unapproved drug imports to make sure they are safe for U.S. patients.

    Doctors say some cancer patients could die if the national shortage of drugs such as cisplatin is not resolved soon. At least 13 other cancer drugs are in short supply across the U.S.

    CNBC Health & Science

    Read CNBC’s latest global health coverage:

    The cancer drug shortages have forced some hospitals to ration medications by reducing the dosage to extend the supply and prioritizing patients who have a better chance of being cured.

    Cisplatin is widely used to treat testicular, lung, bladder, cervical and ovarian cancers among other disease states. Up to 20% of cancer patients are treated with cisplatin and other platinum-based chemotherapy drugs, according to the National Cancer Institute.

    The World Health Organization says the drug is an essential part of basic health care.

    The national shortage of cisplatin began in February after a pharmaceutical company based in India temporarily halted production for the U.S. market.

    Intas Pharmaceuticals decided to temporarily stop production after an FDA inspection last year found a “cascade of failure” in its quality control unit.

    A spokesperson for Intas told CNBC this week the company is working with the FDA to restart production for the U.S., but no date has been set yet.

    [ad_2]

    Source link

  • What You Need To Know About Buying Wholesale CBD – Medical Marijuana Program Connection

    What You Need To Know About Buying Wholesale CBD – Medical Marijuana Program Connection

    [ad_1]

    Get ready for a truth bomb – buying wholesale CBD is a lot like stepping into a labyrinth, except instead of mythical creatures, you’re navigating through a maze of laws, testing, and quality checks. This isn’t a simple trip to the grocery store where you casually toss items into your shopping cart. Oh no, this is a strategic mission, a chess game if you will, and you’re aiming for checkmate.

    So, are you feeling excited about selling CBD? Nervous? A little bit of both?

    These emotions are perfectly normal. In any case, let’s walk through the maze together, and by the end of this article, you’ll be ready to navigate it like a pro.

    Ready to start? Let’s do this.

    You’ve Made Up Your Mind to Buy CBD

    Congratulations! You’ve made a smart move by deciding to jump into the exciting world of selling CBD. CBD products are a hot ticket right now, and it’s no surprise why.

    People from all walks of life are raving about its soothing effects and health benefits. If you’re itching to fill your business with these sought-after products, let’s get down to the nitty-gritty details of how you can get your hands on them in bulk.

    Purchase CBD the Right Way

    Knowledge is power, my friend, and the same holds true when planning to purchase CBD in bulk for your business. Get friendly with the farm bill, stay updated with the FDA’s stance, and keep abreast with your state’s regulations.

    Don’t let the legal jargon intimidate you. It’s just a way to ensure that you’re…

    Original Author Link click here to read complete story..

    [ad_2]

    MMP News Author

    Source link

  • FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns

    FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns

    [ad_1]

    Respiratory syncytial virus viral vaccine under research.

    Hailshadow | Istock | Getty Images

    The U.S. Food and Drug Administration’s independent panel of advisors Thursday recommended full approval of Pfizer’s vaccine that protects infants from respiratory syncytial virus, but raised safety concerns over premature births that may be tied to the shot. 

    The committee unanimously said the vaccine efficacy data was sufficient. Ten of the advisors said the safety data on Pfizer’s shot was adequate, while four said it was not.

    “If the vaccine actually lives up to the data we’ve seen today, I can guarantee many infants and their parents will breathe easier in the coming years,” said Dr. Jay Portnoy, medical director at the Children’s Mercy Hospital in Kansas City, after voting in favor of the safety and efficacy of the shot.

    Dr. Paul Offit, a vaccine expert at the Children’s Hospital of Philadelphia, said he doesn’t believe there is enough data that indicates the safety of the vaccine is “reassuring.” 

    “If you’re in any sense risking premature births with this vaccine, I think there’ll be a big price to pay,” said Offit, who voted against the shot’s safety data. 

    Adam Berger, the director of clinical and healthcare research policy at the National Institutes of Health, voted in favor of the shot’s safety and efficacy, but said Pfizer’s post-marketing studies need to examine the risk of premature births.

    Post-marketing refers to studies conducted on a product after it receives FDA approval.

    The FDA typically follows the advice of its advisory committees but is not required to do so. The agency is slated to make a final decision on the shot in August, right before RSV season in the fall. 

    If approved, Pfizer’s jab would become the world’s first vaccine that protects infants against RSV, a goal scientists have been working toward for decades.

    The FDA earlier this month approved the first RSV shot for adults ages 60 and older from GlaxoSmithKline. The agency is expected to make a decision within weeks on Pfizer’s other RSV shot for that same age group.

    RSV is a common respiratory infection that causes cold-like symptoms. Older adults and younger children are particularly vulnerable to more severe RSV infections. 

    Each year, the virus kills 6,000 to 10,000 seniors and a few hundred children younger than 5, according to the Centers for Disease Control and Prevention. About one out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized, the CDC said.

    Pfizer’s shot for infants is administered to expectant mothers in the late second or third trimester of their pregnancy. The single-dose vaccine triggers antibodies that are passed to the fetus, which provides it with protection against RSV from birth through the first six months of life.

    Weighing safety and efficacy data

    A phase three trial found Pfizer’s shot was nearly 82% effective at preventing severe disease from RSV in newborns during the first 90 days of life. The shot was also about 70% effective during the first six months of the baby’s life.

    But the advisory panel’s concerns stemmed from safety data in that trial. 

    A slightly higher number of premature births occurred among mothers who took the shot compared to those who received a placebo: 5.7% versus 4.7%, respectively. 

    Both Pfizer and the FDA said the difference does not appear to be statistically significant. 

    Most infants, even when born prematurely, were also delivered after 34 weeks of pregnancy, just a few weeks shy of their due dates.

    But Dr. Hana El Sahly, who chairs the FDA advisory committee, said “even if it is late preterm delivery, the fact that we’re putting them into preterm delivery while we’re sitting here debating the matter intellectually is not trivial.”

    Premature deliveries aren’t a new issue when it comes to RSV vaccines for infants.

    Pfizer’s rival GSK halted its own trial on its RSV shot for newborns after noticing concerning data on preterm births and neonatal deaths, or when a baby dies during the first 28 days of life.

    Offit also said GSK’s trial is “hanging over” Pfizer’s own RSV shot for infants. 

    “If GSK truly abandons a program on a similar, almost identical vaccine, that is going to hang over [Pfizer’s] program,” he said during the meeting. “I think it does need to be addressed.”

    Portnoy added preterm deliveries could potentially dampen the benefits of the shot. 

    “The problem is if the child is born earlier, that also reduces the efficacy of the treatment because earlier birth means less antibodies are transferred,” he said. “So, this is a very complex thing because now the harm actually makes the benefit less so. There’s an interaction between the two.” 

    But some panel members cast doubt on whether there’s a clear causal relationship between the vaccine and preterm births. 

    “Am I concerned about the preterm birth imbalance? Yes. Am I convinced that it’s real? No,” said Dr. Daniel Feikin, a scientific advisor and respiratory diseases consultant, who voted in favor of the shot’s safety. 

    Representatives from Pfizer also pushed back on the safety concerns, emphasizing the benefits of the shot outweigh the risks.

    “Certainly, in our eyes, there is no definitive evidence to suggest there is a risk of prematurity,” said Dr. William Gruber, Pfizer’s senior vice president of vaccine clinical research and development. “So the question is, do you hold hostage the potential benefits of the vaccine for something which you have no statistical significance at this point?”

    Some of the participants’ children also had low birth weights and experienced developmental delays, the FDA staff review said.

    Most of the more than 3,000 mothers who received the shot in the trial experienced mild to moderate adverse reactions, according to the FDA staff’s review of data.

    The most common reactions were fatigue, muscle pain, headache and pain at the injection site. Most reactions resolved within three to four days after vaccination, the staff review noted.

    [ad_2]

    Source link

  • American Food Will Never Look Natural Again

    American Food Will Never Look Natural Again

    [ad_1]

    In 1856, an amateur chemist named William Henry Perkin mixed a batch of chemicals that he hoped, in vain, would yield the malaria drug quinine. When Perkin’s failed experiment turned purple, a hue so vivid that it could stain silks without fading, he realized he’d stumbled upon a different marvel of modernity: a commercially viable synthetic dye, the first of a new generation of chemicals that would revolutionize the way humans colored their clothes and, soon after, their food.

    The edible versions of the chemicals, in particular, were a revelation, offering food manufacturers ”cheap and convenient” alternatives to pigments squeezed painstakingly from natural sources such as plants, says Ai Hisano, a historian and the author of Visualizing Taste: How Business Changed the Look of What You Eat. Dyes could keep peas verdant after canning and sausages pink after cooking; they could turn too-green oranges more orange and light up corner-shop candy displays. By the Second World War, synthetic dyes had become, as one grocer put it, “one of the greatest forces in the world” in the sale of foods. And the more foods the chemicals were introduced to, the more the chemicals came to define how those foods should look: the yellow of butter, the crimson of strawberry Jell-O.

    But after hitting a mid-20th-century peak, the roster of synthetic dyes used in Western foods began to shrink. In recent years, European countries have appended warning labels onto the products that contain them; the United States has whittled down its once-long list of approved artificial food dyes to just nine. The FDA is now reviewing a petition to delist Red No. 3, which colors candy corn, conversation hearts, and certain chewing gums and cake icings; California and New York are mulling legislation that could ban the additive, along with several others, by 2025.

    The concern is that the dyes add not just colors but a substantial health risk. Several of the compounds have been linked to patterns of hyperactivity and restlessness in kids. Red No. 3 has also been known since the 1980s to cause cancer in rats. The precise explanation for the harm is unclear; research into the issue has been spotty, and “there is no comprehensive set of data that says, ‘This is the mechanism,’” according to Elad Tako, a food scientist at Cornell University. Several respected researchers have even dismissed the evidence as overhyped. More than a century into the dyes’ tenure, “there is not even consensus on the fact that they are dangerous,” or what happens when our bodies snarf them down, says Monica Giusti, a food scientist at Ohio State University.

    Even so, the argument against artificial food dyes seems as though it should be simple: They have no known nutritional benefits and potentially carry several health risks. “We’re talking about something that’s cosmetic versus something that is hurting kids,” says Lisa Lefferts, an environmental-health consultant who has petitioned the FDA to ban Red No. 3. And yet, the dyes endure—precisely because they offer our foods and our eyes shades that nature never could.


    When synthetic food dyes were newer, their shortcomings were hard to miss. One of the colorants’ main ingredients was derived from the by-products of the process that turned coal into fuel—and in the absence of careful scrutiny, some early batches of the dyes ended up contaminated with arsenic, mercury, and lead. Companies also used the dyes to conceal defects or spoilage that then sickened many people. By the 1930s, Congress required, among other safety measures, that government scientists vet the chemicals’ safety and restricted companies to sourcing exclusively from an approved list.

    But dangerous chemicals seemed to keep slipping through. In the 1950s, after a batch of Halloween candy sickened several children, FDA scientists found that the culprit was the synthetic dye that had turned the treats orange—a dye so toxic that it caused organ damage and even premature death in animals in labs. The agency hastily banned it and, by the late 70s, axed nearly a dozen other synthetic dyes linked to cancers and organ damage in animals. Today, Americans regularly see just seven artificial dyes in their foods; two others are used very sparingly.

    Still, roughly 19 million pounds of the seven prevalent synthetic dyes were certified by the FDA to flood the U.S. food supply in fiscal year 2022—and no one agrees on which colorants pose the biggest threat. In the European Union and the United Kingdom, foods containing any of six synthetic food dyes—including the three most common ones in the U.S.: Red No. 40, Yellow No. 5, and Yellow No. 6—must warn customers that the colorants “may have an adverse effect on activity and attention in children.” The FDA, however, has yet to adopt any such posture—even though it’s long since delisted Red No. 2, which is still allowed in Europe. Even Red No. 3—which has been linked to both cancer in animals and behavioral issues in kids, and may be one of the most concerning additives remaining in the American food supply, according to Peter Lurie, the president and executive director of the Center for Science in the Public Interest—carries a mixed rap. The FDA banned it from cosmetics and externally applied drugs decades ago but still allows it in food; countries in Europe have restricted its use but don’t mind adding it to certain canned cherries to maintain their hue.

    On the whole, the International Association of Color Manufacturers, which represents the color-additives industry, told me that the claims around food dyes and health risks aren’t sound, pointing out that many of the studies on synthetic colors have yielded conflicting results. The FDA, too, maintains that color additives “are very safe when used properly.” The links, to be fair, are tough to study: With behavior-focused outcomes in kids, for instance, “you’re looking at more subtle kinds of changes that you find on a population basis,” and some children seem more sensitive than others, further muddying the stats, says Linda Birnbaum, the former director of the National Institute of Environmental Health Sciences and the National Toxicology Program. And some laboratory studies on the chemicals have delivered them into rodents in high doses or via tubes down their throat, making the data’s relevance to us a bit shakier. But although some argue that there’s not enough evidence to conclude that the dyes definitely pose a peril, others rightly note that there’s also insufficient data to conclude that they don’t. For all of the pounds of the chemicals we’ve gulped down, “there are still more questions than answers about artificial colorants,” says Diego Luna-Vital, a food scientist at the Monterrey Institute of Technology and Higher Education, in Mexico.

    Lefferts, the environmental-health consultant, is one of several researchers who’d rather err on the side of caution and expunge the entire current roster of artificial food dyes. The potential losses seem negligible, she told me, and the possible benefits immense. Scientists may not even yet know the extent of the dyes’ issues: Just last year, a group led by Waliul Khan of McMaster University published evidence that Red No. 40 may raise the risk of colitis in mice. But without an outright push from the FDA, manufacturers have little incentive to change their practices. And there’s not exactly a clear-cut path toward developing new synthetic colorants with a less dubious safety profile: Without identifying why current dyes might be dangerous, scientists can’t purposefully avoid the root problem in future ones, says Thomas Galligan, CSPI’s principal scientist for food additives and supplements.


    In the background of the fight over artificial dyes, the colorants’ natural counterparts are making a slow and steady comeback. In the EU and the U.K., consumers can find Starburst and M&M’s tinted mostly with plant extracts. And in the U.S., Kraft has re-created the artificial-orange hue of its mac and cheese with a blend of annatto, turmeric, and paprika. Recent surveys have shown that a growing contingent of the global population is eager to eat cleaner ingredients—not, as Jim Murphy, the former president of General Mills, once put it, “colors with numbers in their foods.”

    But in late 2017, Murphy would go on to eat his words, after his company’s all-natural version of Trix debuted, then rapidly tanked. Trix traditionalists were horrified at the revamped recipe’s muted melange of purple-y reds and orangey yellows, devoid of the greens and blues that General Mills had struggled to naturally replicate; they called it “disgusting,” and “basically a salad now.” Just two years after pledging to purge its products of artificial additives, General Mills reinstated “classic Trix”—complete with its synthetics-laden ingredient list. A similar story played out with Necco, which removed the artificial dyes from its wafers only to quickly return them; Mars, too, publicly promised to remove synthetics from its American products then let its self-imposed deadline pass without making good.

    Natural dyes, it turns out, are still a chore to work with, for the same reasons they were once so easily replaced. They’re expensive to extract and process; their colors are inconsistent, and tend to fade quite fast, especially in the presence of light and heat, Luna-Vital told me. Humans are also limited to what nature has available, and the fickleness of those compounds: They often “change on us,” Giusti told me, when researchers mix them into recipes. Sometimes the colors even impart unwanted flavors or funk.

    Several companies, including Sensient and Kalsec, told me that they are now trying to introduce modifications or tweaks that enhance natural pigments’ stability and vibrancy to help them compete. But the more tinkering happens, the more these new dyes could start to resemble the ones that researchers want them to oust. Nowadays, even natural colorants “are artificially created, on some level,” Hisano, the historian, told me. And although the FDA’s regulatory standards assume that plant-, animal-, and mineral-derived dyes will be a safer alternative to synthetics, going as far as to exempt them from certain tests, relying on the simple reassurance that a source is natural is, admittedly, “not the strongest scientific argument,” Michael Jacobson, the former executive director of CSPI, told me. Nature-made, after all, has never been synonymous with safe: It wasn’t so long ago that bakers were bleaching their breads with chalk and dairy manufacturers were tingeing their milks yellow with lead chromate. (“The FDA’s regulations require evidence that a color additive is safe at its intended level of use before it may be added to foods,” a spokesperson told me.)

    There is, technically, another option—abstaining from adding colors to foods at all. But that would fundamentally transform how we experience our meals. Added dyes and pigments—both artificial and natural—are mainstays not just of sports drinks and packaged sweets but also salad dressing, yogurt, pickles, peanut butter, and dried and smoked meats; they’re what makes farmed-salmon flesh pink. Vision is key to taste: “There’s probably no other sensory cue that gives us as much information about what we’re about to eat,” says Charles Spence, an experimental psychologist at the University of Oxford. In what might be an echo of the preferences that helped our ancestors find ripe fruits, Spence told me, our modern brain still tends to link pinks and reds to sugar and yellows and greens to all things tart. Colors can play tricks too: When researchers artificially darken the tint of drinks or yogurt, study subjects insist that it tastes sweeter; when consumers see a rainbow of flavors in their snacks, the sheer appeal of variety may persuade some of them to eat more.

    Some of artificial dyes’ biggest dangers, then, may not even be entirely inherent to the chemicals themselves. Foods that need a color boost tend to be the ones that experts already want us to avoid: candies, sodas, and packaged, processed snacks, especially those marketed to children, points out Lindsay Moyer, a CSPI nutritionist. Colors so exaggerated, so surprising, so unnatural inevitably tempt kids “to reach out of the grocery cart,” Moyer told me. Dyes, once cooked up by us to mimic and juxtapose with the natural world, have long since altered us—manipulating our base instincts, warping our appetites—and transformed into a luxury that the world now seems entirely unable to quit.


    ​When you buy a book using a link on this page, we receive a commission. Thank you for supporting The Atlantic.

    [ad_2]

    Katherine J. Wu

    Source link